The Expanded Access Summit®, now in virtual form, is our flagship event and the world’s largest annual conference on pre-market access to medicines. The Summit focuses on feasibility for all stakeholders and the integration of well-designed access programs in the modern clinical development process. We work to to continually establish new best practices, dispel prevailing myths, and break through the most stubborn barriers to innovation.

Janet Woodcock, MD; FDA
Expanded Access 3.0, January 28, 2020

Hilary Marston, MD, MPH; NIAID, NIH
Expanded Access 3.0, January 28, 2020

Michael Kurilla, MD, PhD; NCATS, NIH
Expanded Access 3.0, January 28, 2020

The Expanded Access Summit® was launched in 2017 to provide a best-practices forum for thought leaders from the highest level of leadership in industry, clinical care, patient advocacy, and government. It has since become the world’s largest and most influential annual conference on pre-market access to medicines. 

Previous Speakers Include:

Janet WoodCock, MD
Director, Center for Drug Evaluation and Research, FDA
Toni Fauci, MD
Director, National Institute of Allergy and Infectious Diseases (NIAID), NIH
Chris Austin, MD
Director, National Center for Advancing Translational Sciences, NIH
Frank Young, MD, PHD
Executive Vice President Clinical & Reg Affairs, TissueTech Inc.; Former FDA Commissioner, 1984-1989
Marjorie Speers, PhD
Executive Director, Clinical Research Pathways
MICHAEL KURILLA, MD, PHD
Director of the Division of Clinical Innovation, NCATS-NIH
MARC BOUTIN, JD
Chief Executive Officer, National Health Council
SUANNA BRUINOOGE, MPH
Director of Research Strategy, CENTRA, American Society of Clinical Oncology (ASCO)

Each year the Summit examines the four major feasibility factors of pre-market access:

Operational efficiency

Learning outcomes and research value

Financial collaboration, cost recovery, and reimbursement from payers

Alignment with healthcare delivery organizations

Register Now

Expanded Access 4.0 (virtual conference)

April 26-29, 2021

The 4th Annual Expanded Access Summit® The Leading Global Forum on Pre-Market Access to Medicines
Type Early Bird (by March 15) Standard Pricing
Corporate $650 $895
Health System, Gov’t, Non-Profit $150 $200
Public (Guest Pass) $50 $60
Entrepreneur Contact us --

Join Our Pre-Registration List for
Expanded Access 4.0

(virtual conference)

2020 Sponsors and Partners

inceptua-logo
global-guide-to-compassionate-use-programs
mytomorrows-logo
early-access-care
anova
WEP-clinical
WideTrial-logo
tanner-pharma-logo
durbin-logo